DAR-T

DAR-T (Dual Antigen Receptor T-cell) is a proprietary cell therapy platform developed by Celyad Oncology designed to address the limitations of traditional CAR-T therapies, particularly in the context of allogeneic (off-the-shelf) applications and solid tumors. The DAR-T technology involves the engineering of T-cells to express a Dual Antigen Receptor, which typically combines a chimeric antigen receptor (CAR) with a second functional component, such as a T-cell receptor (TCR) inhibitory molecule or a second targeting domain. A key feature of the DAR-T platform is its ability to selectively eliminate or suppress specific cell populations, such as alloreactive T-cells, to prevent Graft-versus-Host Disease (GvHD) without the need for complex gene editing (like CRISPR or TALENs). By utilizing a non-gene-edited approach to TCR knockdown, DAR-T cells can be manufactured more efficiently for allogeneic use. The primary clinical candidate from this platform, CYAD-211, was designed to target B-cell maturation antigen (BCMA) for the treatment of multiple myeloma while simultaneously suppressing the TCR complex to enable allogeneic administration.

Other names

D-antigen-specific receptor T-cellsDual Antigen Receptor T-cell